U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula O4P
Molecular Weight 94.9714
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge -3

SHOW SMILES / InChI
Structure of Phosphate ion

SMILES

[O-]P([O-])([O-])=O

InChI

InChIKey=NBIIXXVUZAFLBC-UHFFFAOYSA-K
InChI=1S/H3O4P/c1-5(2,3)4/h(H3,1,2,3,4)/p-3

HIDE SMILES / InChI

Molecular Formula H3O4P
Molecular Weight 97.9952
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Phosphate is a major intracellular anion in mammals. Hydrogen phopshate is a protonated form of phosphate. In serum, phosphate exists in two forms, dihydrogen phosphate (H2PO4) and its salt, mono-hydrogen phosphate (HPO4). At the physiologic pH of 7.40, the pK of H2PO4 is 6.8 and the ratio of HPO4 to H2PO4 is 4:1. Altered level of phosphate can be an indicator of various disorders, such as chronic renal failure, hypoparathyroidism, familial intermittent hyperphosphatemia, endocrine disorders, hyperthyroidism, acromegaly, juvenile hypogonadism, etc. These disorders may lead to either hyper- or hypophosphatemia, which can be caused by cellular shifts of phosphate. Patients with hypophosphatemia can be treated with dietary phosphate supplements (potassium phosphate, for example).

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
PROCALAMINE

Approved Use

ProcalAmine is indicated for peripheral administration in adults to preserve body protein and improve nitrogen balance in well-nourished, mildly catabolic patients who require short-term parenteral nutrition.

Launch Date

1982
Palliative
Unknown

Approved Use

Unknown
Palliative
Unknown

Approved Use

Unknown
Palliative
Unknown

Approved Use

Unknown
Palliative
Unknown

Approved Use

Unknown
Diagnostic
Unknown

Approved Use

Unknown
Diagnostic
Unknown

Approved Use

Unknown
Primary
SODIUM PHOSPHATES INJECTION

Approved Use

Sodium Phosphates Injection, USP, 3mM P/mL, is indicated as a source of phosphorus, for addition to large volume intravenous fluids, to prevent or correct hypophosphatemia in patients with restricted or no oral intake. It is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions. The concomitant amount of sodium (4 mEq/mL) must be calculated into total electrolyte content of such prepared solutions.
PubMed

PubMed

TitleDatePubMed
Patents

Patents

Sample Use Guides

lose body protein: approximately three liters per day of ProcalAmine will provide a total of 90 grams of amino acids, 390 nonprotein calories and the recommended daily intake of principal intra- and extracellular electrolytes for the stable patient. Therapy can begin with three liters of ProcalAmine on the first day with close monitoring of the patient. As with all intravenous fluid therapy, the goal is to provide adequate water to compensate for insensible, urinary and other losses, and electrolytes for replacement and maintenance. These requirements should be determined frequently and appropriately administered. Additional electrolytes should be administered evenly throughout the day, and irritating medications should be injected at an alternate infusion site. Pediatric Use ProcalAmine is intended for use in adults. Use of ProcalAmine in pediatric patients is governed by the same considerations that affect the use of any amino acid solution in pediatrics. The amount administered is dosed on the basis of grams of amino acids/kg of body weight/day. Two to three g/kg of body weight for infants with adequate calories are generally sufficient to satisfy protein needs and promote positive nitrogen balance. Solutions administered by peripheral vein should not exceed twice normal serum osmolarity (718 mOsmol/L). Venous irritation at an infusion site can be minimized by the selection of a large peripheral vein as well as by slowing the rate of infusion. In pediatric patients, the final solution should not exceed twice normal serum osmolarity (718 mOsmol/L). nausea: for maximum effectiveness never dilute or drink fluids of any kind immediately before or after taking this product. Adults and children 12 years of age and over: one or two tablespoons; children 2 to under 12: one or two teaspoons; repeat dose every 15 minutes or until distress subsides; do not take more than 5 doses in 1 hour without consulting a doctor.
Route of Administration: Other
37% phosphoric acid, 17% EDTA, 10% citric acid, 2% chlorhexidine (solution and gel), and 5.25% NaOCl were tested their antimicrobial activity was tested against Candida albicans, Staphylococcus aureus, Enterococcus faecalis, Escherichia coli, Actinomyces meyeri, Parvimonas micra, Porphyromonas gingivalis, and Prevotella nigrescens according to the agar diffusion method. The cytotoxicity of the irrigants was determined by using the MTT assay. Phosphoric acid presented higher antimicrobial activity compared to the other tested irrigants.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:35:33 GMT 2025
Edited
by admin
on Mon Mar 31 18:35:33 GMT 2025
Record UNII
NK08V8K8HR
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PHOSPHATE
MART.   VANDF  
Preferred Name English
Phosphate ion
Common Name English
SERUM PHOSPHATE
Common Name English
PHOSPHATE [VANDF]
Common Name English
ORTHOPHOSPHATE
Systematic Name English
PHOSPHATE(3-)
Common Name English
SODIUM ALENDRONATE TRIHYDRATE IMPURITY B [EP IMPURITY]
Common Name English
O-PHOSPHATE
Common Name English
PHOSPHATE [MART.]
Common Name English
Classification Tree Code System Code
LOINC 35222-9
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 87457-8
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 87456-0
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 58019-1
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 11141-9
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 21458-5
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 88713-3
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 25127-2
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 14881-7
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 2781-3
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 27123-9
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 14406-3
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 24520-9
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 2777-1
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 34938-1
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 35673-3
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 20941-1
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 30544-1
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 14405-5
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 2778-9
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 10884-5
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 24519-1
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 2782-1
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 14408-9
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 25501-8
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 35220-3
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 57349-3
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 14407-1
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 13539-2
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 57348-5
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 49006-0
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 34354-1
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 13795-0
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 14879-1
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 80611-7
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 35263-3
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 14404-8
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 59037-2
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 17447-4
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 2775-5
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 55973-2
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 56964-0
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 2774-8
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 2780-5
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 59167-7
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 56965-7
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 14880-9
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 59161-0
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 22733-0
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 50898-6
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 51604-7
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 16525-8
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 13543-4
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 2779-7
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 12242-4
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 76656-8
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 74889-7
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 35221-1
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 14878-3
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 13542-6
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 58993-7
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 25973-9
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
LOINC 54922-0
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
Code System Code Type Description
PUBCHEM
1061
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
PRIMARY
CHEBI
18367
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
PRIMARY
CHEBI
35780
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
PRIMARY
EPA CompTox
DTXSID7039672
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
PRIMARY
CHEBI
26078
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
PRIMARY
CHEBI
43474
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
PRIMARY
RXCUI
486961
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
PRIMARY RxNorm
RXCUI
1793924
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
PRIMARY
WIKIPEDIA
PHOSPHATE
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
PRIMARY
CAS
14265-44-2
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
PRIMARY
EVMPD
SUB16456MIG
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
PRIMARY
DRUG BANK
DB14523
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
PRIMARY
FDA UNII
NK08V8K8HR
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
PRIMARY
SMS_ID
100000078587
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
PRIMARY
DAILYMED
NK08V8K8HR
Created by admin on Mon Mar 31 18:35:33 GMT 2025 , Edited by admin on Mon Mar 31 18:35:33 GMT 2025
PRIMARY
Related Record Type Details
LIGAND->TARGET
IONIC MOIETY
Related Record Type Details
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY